Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition

Giulia Pinton; Zhuo Wang; Cecilia Balzano; Sara Missaglia; Daniela Tavian; Renzo Boldorini; Dean A. Fennell; Martin Griffin; Laura Moro

doi:10.3389/fonc.2022.1081632

Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition

Giulia Pinton^*, Zhuo Wang, Cecilia Balzano, Sara Missaglia, Daniela Tavian, Renzo Boldorini, Dean A. Fennell, Martin Griffin, Laura Moro^*

^*Corresponding author for this work

Research output: Contribution to journal › Correction › peer-review

Original language	English
Article number	1081632
Number of pages	1
Journal	Frontiers in Oncology
Volume	12
Early online date	23 Nov 2022
DOIs	https://doi.org/10.3389/fonc.2022.1081632
Publication status	Published - 23 Nov 2022

Bibliographical note

Copyright © 2022 Pinton, Wang, Balzano, Missaglia, Tavian, Boldorini, Fennell, Griffin and Moro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Funding Information:
In the original article, there was an error in the Funding statement as published. The correct funding statement is “The authors acknowledge the financial support of project HERMES (HEreditary Risk in MESothelioma) and Università del Piemonte Orientale (Bando ricerca locale 2019)”.

Keywords

Oncology
malignant pleural mesothelioma
EZH2 inhibitor
CDKN2A/p16ink4a
TG2
multicellular spheroids

Access to Document

10.3389/fonc.2022.1081632Licence: CC BY 4.0

fonc-12-1081632.pdf
Missaglia, Tavian, Boldorini, Fennell, Griffin and Moro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Final published version, 261 KBLicence: CC BY 4.0

Cite this

@article{fe196aa4f57d40f59b18c310223f2a8f,

title = "Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition",

keywords = "Oncology, malignant pleural mesothelioma, EZH2 inhibitor, CDKN2A/p16ink4a, TG2, multicellular spheroids",

author = "Giulia Pinton and Zhuo Wang and Cecilia Balzano and Sara Missaglia and Daniela Tavian and Renzo Boldorini and Fennell, {Dean A.} and Martin Griffin and Laura Moro",

note = "Copyright {\textcopyright} 2022 Pinton, Wang, Balzano, Missaglia, Tavian, Boldorini, Fennell, Griffin and Moro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Funding Information: In the original article, there was an error in the Funding statement as published. The correct funding statement is “The authors acknowledge the financial support of project HERMES (HEreditary Risk in MESothelioma) and Universit{\`a} del Piemonte Orientale (Bando ricerca locale 2019)”. ",

year = "2022",

month = nov,

day = "23",

doi = "10.3389/fonc.2022.1081632",

language = "English",

volume = "12",

}

TY - JOUR

T1 - Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition

AU - Pinton, Giulia

AU - Wang, Zhuo

AU - Balzano, Cecilia

AU - Missaglia, Sara

AU - Tavian, Daniela

AU - Boldorini, Renzo

AU - Fennell, Dean A.

AU - Griffin, Martin

AU - Moro, Laura

N1 - Copyright © 2022 Pinton, Wang, Balzano, Missaglia, Tavian, Boldorini, Fennell, Griffin and Moro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Funding Information: In the original article, there was an error in the Funding statement as published. The correct funding statement is “The authors acknowledge the financial support of project HERMES (HEreditary Risk in MESothelioma) and Università del Piemonte Orientale (Bando ricerca locale 2019)”.

PY - 2022/11/23

Y1 - 2022/11/23

KW - Oncology

KW - malignant pleural mesothelioma

KW - EZH2 inhibitor

KW - CDKN2A/p16ink4a

KW - TG2

KW - multicellular spheroids

UR - https://www.frontiersin.org/articles/10.3389/fonc.2022.1081632/full

UR - http://www.scopus.com/inward/record.url?scp=85143394472&partnerID=8YFLogxK

U2 - 10.3389/fonc.2022.1081632

DO - 10.3389/fonc.2022.1081632

M3 - Correction

C2 - 36505807

VL - 12

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1081632

ER -

Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition

Bibliographical note

Keywords

Access to Document

Other files and links

Cite this